Breath of Life Pharma

Cannabis-related Products

Health Tech & Life Sciences
Non Active, Apr 2025 ceased to operate

Company Overview

Snapshot

Founded in January 2007, Breath of Life Pharma operates with 11–50 employees. The company has raised $35 million across two funding rounds from four investors. In November 2020, OurCrowd participated in a funding round for the company.

Business overview

Breath of Life Pharma develops cannabinoid-based drugs and botanical-derived products to enhance patient health and quality of life. The company cultivates proprietary cannabis strains, operates certified labs, and manages a plant and distribution center. It targets the medical cannabis, wellness, and pharmaceutical markets, with a pharmaceutical division focused on an inhaler-based drug delivery platform for selected pain indications, including multiple sclerosis-related neuropathic pain, chemotherapy-induced pain, and HIV-induced neuropathic pain. The core technology involves a pressurized metered dose inhaler (pMDI) containing cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC), offering an efficient and consistent administration route that bypasses irregular gastrointestinal absorption and first-pass hepatic metabolism.

Strategic signal

In December 2020, Kindeva and BOL Pharma signed an agreement for the development of inhaled cannabinoid products. This partnership signals a strategic focus on advanced drug delivery methods for cannabis-based therapies, aiming to improve bioavailability and patient experience, which could significantly impact the medical cannabis and pharmaceutical sectors by offering more effective treatment options.

Company Intelligence Q&A

What is the primary focus of Breath of Life Pharma's pharmaceutical division?
Breath of Life Pharma's pharmaceutical division has launched a spinoff company focused on an inhaler based on a Kindeva drug delivery platform for selected pain indications, with multiple sclerosis-related neuropathic pain as its lead indication.
When did Breath of Life Pharma complete Israel's first cannabis export?
In January 2020, Breath of Life Pharma completed Israel's first-ever cannabis export, with LYPHE Group importing into the UK.
Which investors participated in Breath of Life Pharma's October 2018 funding round?
In October 2018, Breath of Life Pharma received funding from Gandyr Investments, OurCrowd, Leon Koffler, and Amir Marketing.
What was the outcome of Breath of Life Pharma's planned Toronto IPO?
In June 2019, Breath of Life Pharma delayed its Toronto IPO and slashed 17% off its pre-IPO valuation.
What is the status of Breath of Life Pharma as of April 2025?
Breath of Life Pharma ceased to operate in April 2025.

External links